1
|
Couacault P, Avella D, Londoño‐Osorio S, Lorenzo AS, Gradillas A, Kärkkäinen O, Want E, Witting M. Targeted and untargeted metabolomics and lipidomics in dried blood microsampling: Recent applications and perspectives. ANALYTICAL SCIENCE ADVANCES 2024; 5:e2400002. [PMID: 38948320 PMCID: PMC11210747 DOI: 10.1002/ansa.202400002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 05/13/2024] [Accepted: 05/14/2024] [Indexed: 07/02/2024]
Abstract
Blood microsampling (BµS) offers an alternative to conventional methods that use plasma or serum for profiling human health, being minimally invasive and cost effective, especially beneficial for vulnerable populations. We present a non-systematic review that offers a synopsis of the analytical methods, applications and perspectives related to dry blood microsampling in targeted and untargeted metabolomics and lipidomics research in the years 2022 and 2023. BµS shows potential in neonatal and paediatric studies, therapeutic drug monitoring, metabolite screening, biomarker research, sports supervision, clinical disorders studies and forensic toxicology. Notably, dried blood spots and volumetric absorptive microsampling options have been more extensively studied than other volumetric technologies. Therefore, we suggest that a further investigation and application of the volumetric technologies will contribute to the use of BµS as an alternative to conventional methods. Conversely, we support the idea that harmonisation of the analytical methods when using BµS would have a positive impact on its implementation.
Collapse
Affiliation(s)
- Pauline Couacault
- Metabolomics and Proteomics CoreHelmholtz Zentrum MünchenNeuherbergGermany
| | - Dennisse Avella
- Afekta Technologies Ltd.KuopioFinland
- School of PharmacyFaculty of Health SciencesUniversity of Eastern FinlandKuopioFinland
| | - Sara Londoño‐Osorio
- Centro de Metabolómica y Bioanálisis (CEMBIO)Facultad de FarmaciaUniversidad San Pablo‐CEUCEU UniversitiesUrbanización MontepríncipeBoadilla del MonteMadridSpain
| | - Ana S. Lorenzo
- Department of MetabolismDigestion and ReproductionImperial College LondonLondonUK
| | - Ana Gradillas
- Centro de Metabolómica y Bioanálisis (CEMBIO)Facultad de FarmaciaUniversidad San Pablo‐CEUCEU UniversitiesUrbanización MontepríncipeBoadilla del MonteMadridSpain
| | - Olli Kärkkäinen
- Afekta Technologies Ltd.KuopioFinland
- School of PharmacyFaculty of Health SciencesUniversity of Eastern FinlandKuopioFinland
| | - Elizabeth Want
- Department of MetabolismDigestion and ReproductionImperial College LondonLondonUK
| | - Michael Witting
- Metabolomics and Proteomics CoreHelmholtz Zentrum MünchenNeuherbergGermany
- Chair of Analytical Food ChemistryTUM School of Life SciencesTechnical University of MunichFreising‐WeihenstephanGermany
| |
Collapse
|
2
|
Mazzarino M, Al-Mohammed H, Al-Darwish SK, Salama S, Al-Kaabi A, Samsam W, Kraiem S, Botré F, Beotra A, Mohamed-Ali V, Al-Maadheed M. Liquid vs dried blood matrices: Application to longitudinal monitoring of androstenedione, testosterone, and IGF-1 by LC-MS-based techniques. J Pharm Biomed Anal 2024; 242:116007. [PMID: 38367516 DOI: 10.1016/j.jpba.2024.116007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 01/17/2024] [Accepted: 01/31/2024] [Indexed: 02/19/2024]
Abstract
BACKGROUND Dried blood spots have recently been approved by the World Anti-Doping Agency as an alternative biological matrix for testing of doping substances. However, their use is limited to the detection of non-threshold compounds without a Minimum Reporting Level due to the numerous issues related to quantitative analyses and the limitation on testing capabilities of a haemolysed matrix. AIM In this study androstenedione, testosterone and IGF-1 were longitudinally monitored in four different blood matrices to evaluate the potential of liquid capillary blood as an alternative matrix for quantitative determination in doping control analysis. METHODOLOGY The analytical protocols developed to pretreat 20 μL of the blood matrices selected were based: i) for testosterone and androstenedione, on supported liquid extraction for liquid blood matrices, and on ultrasonication in the presence of methanol for dried blood matrices; ii) for IGF-1, proteins precipitation followed by evaporation of the supernatant was used to pretreat both liquid and dried blood matrices. The detection for all the target analytes was performed using liquid chromatography coupled to mass spectrometry. The analytical workflows, once optimized, were fully validated according to the requirements of World Anti-Doping Agency and ISO 17025 standard and used for the analysis of venous (serum) and capillary (liquid plasma and dried whole blood collected using either volumetric or non-volumetric devices) blood samples collected from 7 healthy subjects. RESULTS The validation results showed satisfactory performance as related to specificity, sensitivity, matrix effects, linearity, accuracy, and precision in all the blood matrices evaluated despite the limited volume of sample used. The analysis of the different blood matrices collected from the subjects showed non-significant differences between the levels of testosterone and androstenedione measured in dried (fixed volume collected) and liquid matrices. An acceptable underestimation (lower than 15 %) was observed in capillary plasma compared to venous serum. The testosterone/androstenedione ratio was similar in all the blood matrices considered (bias lower than 5 %), indicating this parameter was not affected by either the blood matrix or collection device selected. For IGF-1, the levels measured in liquid blood matrices differed significantly (bias higher than 20 %) from those measured in dried whole blood matrices, suggesting haemolyzed blood might represent a challenge for the determination of macromolecules, mainly due to the complexity of the whole blood matrix in comparison to plasma/serum. NOVELTY The outcomes of our study suggest that liquid capillary blood might open new avenues to blood microsampling in doping control field. It represents an efficient alternative to overcome the issues related to venous blood and dried blood spot sampling. Furthermore, it also allows greater frequency of blood sampling, with minor discomfort and without needing a phlebotomist, for analyses that can only be performed in blood samples, with an increased probability to detect and report Adverse Analytical Finding.
Collapse
Affiliation(s)
- Monica Mazzarino
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | - Hana Al-Mohammed
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | | | - Sofia Salama
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | - AlAnoud Al-Kaabi
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | - Waseem Samsam
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | - Suhail Kraiem
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | - Francesco Botré
- Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti 1, 00197, Italy; REDs - Research and Expertise on Doping in Sport, ISSUL - Institute of Sport Sciences, University of Lausanne, Synathlon - Quartier Centre, Lausanne 1015, Switzerland
| | - Alka Beotra
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar
| | - Vidya Mohamed-Ali
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar; Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Road, London NW3 2PF, UK
| | - Mohammed Al-Maadheed
- Anti-Doping Laboratory Qatar, Aspire Zone 54, Street 665, Doha, Qatar; Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Road, London NW3 2PF, UK.
| |
Collapse
|
3
|
Levernaes MCS, Solheim SA, Broderstad L, Zandy E, Mørkeberg J, Dehnes Y. Detection of doping substances in paired dried blood spots and urine samples collected during doping controls in Danish fitness centers. Drug Test Anal 2024. [PMID: 38433478 DOI: 10.1002/dta.3660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 01/16/2024] [Accepted: 01/31/2024] [Indexed: 03/05/2024]
Abstract
The use of dried blood spot (DBS) in anti-doping can be advantageous in terms of collection, transportation, and storage compared with the traditional anti-doping testing matrices urine and venous blood. There could, nonetheless, be disadvantages such as shorter detection windows for some substances compared with urine, but real-life comparison of the detectability of prohibited substances in DBS and urine is lacking. Herein, we present a liquid chromatography-high resolution mass spectrometry (LC-HRMS)-based screening method for simultaneous detection of 19 target analytes from the doping substance categories S1-S5 in a single spot. Ninety-eight urine and upper-arm DBS (Tasso-M20) sample pairs were collected from fitness centers customers notified for doping control by Anti Doping Denmark, and three sample pairs were collected from active steroid users undergoing clinical evaluation and treatment at a Danish hospital. The analytical findings were cross compared to evaluate the applicability of the developed DBS testing menu in terms of feasibility and analytical performance. To our knowledge, this is the first study to compare the detectability of prohibited substances in DBS and urine samples collected in a doping control setting. Twenty-seven of the urine samples and 23 DBS samples were positive, and we observed a very high concordance (95%) in the overall analytical results (i.e., positive or negative samples for both urine and DBS). Collectively, these results are very promising, and DBS seems suitable as a stand-alone matrix in doping control in fitness centers likely because of the high analyte concentration levels in these samples.
Collapse
Affiliation(s)
| | - Sara A Solheim
- Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway
- Science and Research, Anti Doping Denmark, Brøndby, Denmark
| | - Lillian Broderstad
- Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway
| | - Essa Zandy
- Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway
| | | | - Yvette Dehnes
- Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
4
|
Requena-Tutusaus L, Anselmo I, Alechaga É, Bergés R, Ventura R. Achieving routine application of dried blood spots for erythropoietin receptor agonist analysis in doping control: low-volume single-spot detection at minimum required performance level. Bioanalysis 2023; 15:1235-1246. [PMID: 37676639 DOI: 10.4155/bio-2023-0118] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/08/2023] Open
Abstract
Background: Erythropoietin receptor agonists (ERAs) are substances prohibited in sports and currently monitored in urine and blood. There is a great interest in new matrices like dried blood spots (DBSs). Method: A direct method for the detection of ERAs in DBSs using one single spot of 25 μl has been optimized and validated. Results: Limits of detection close or equal to those required by the World Anti-Doping Agency for serum/plasma samples were achieved, using a volume 20-times lower. All analytes were stable for at least 90 days at room temperature. Conclusion: Method performance was comparable to the requirements established for blood samples and, thus, monitoring of ERAs is reliable in DBSs in the context of doping control.
Collapse
Affiliation(s)
- Lídia Requena-Tutusaus
- Catalonian Antidoping Laboratory, Doping Control Research Group, Fundació IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Department of Experimental & Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Indira Anselmo
- Catalonian Antidoping Laboratory, Doping Control Research Group, Fundació IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Élida Alechaga
- Catalonian Antidoping Laboratory, Doping Control Research Group, Fundació IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Department of Experimental & Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Rosa Bergés
- Catalonian Antidoping Laboratory, Doping Control Research Group, Fundació IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Rosa Ventura
- Catalonian Antidoping Laboratory, Doping Control Research Group, Fundació IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| |
Collapse
|
5
|
Kalita SJ, Pawar SD, Vernekar P, Pawar MA, Veena KS, Mishra KMA, Sethi KK, Radhakrishnanand P, Murty US, Sahu PL, Dubey S, Sahu K, Upadhyay A, Kori RK, Kumar P. Synthesis and characterization of octopamine sulfate, norfenefrine sulfate and etilefrine sulfate reference materials for doping control. JOURNAL OF CHEMICAL TECHNOLOGY & BIOTECHNOLOGY 2023; 98:2318-2329. [DOI: 10.1002/jctb.7458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Accepted: 06/09/2023] [Indexed: 09/25/2023]
Abstract
AbstractBACKGROUNDDoping is the use of prohibited substances by athletes to improve their performance. World Anti‐Doping Agency (WADA)‐accredited laboratories require various metabolite reference standards of the prohibited chemical substances or drugs for routine quality control. Therefore, it was proposed to develop efficient synthetic methodologies for highly pure reference materials of Phase II metabolites of octopamine, norfenefrine and etilefrine, which are prohibited in sports by WADA under the S6 stimulant category. The reference materials were characterized using various analytical techniques. New high‐performance liquid chromatography with diode‐array detection (HPLC‐DAD) methods were developed for purity assessment.RESULTSThe synthesized Phase II metabolite reference standards, i.e. octopamine sulfate, norfenefrine sulfate and etilefrine sulfate, were confirmed by 1H NMR, 13C NMR, liquid chromatography–high‐resolution mass spectrometry (LC‐HRMS), attenuated total reflectance Fourier transform infrared and thermogravimetric analysis. In the LC‐HRMS study, the mass error value of synthesized compounds was less than 10 ppm (error) which confirms the identity of the reference materials. New HPLC‐DAD method were developed to ensure the purity of the reference materials. We used the HILIC column as metabolite reference standards are highly polar. The mobile phase was composed of water and acetonitrile in fixed composition. The HPLC‐DAD purity of the developed reference materials was observed as 100%.CONCLUSIONWe have developed reproducible synthetic routes for octopamine sulfate, norfenefrine sulfate and etilefrine sulfate, which are prohibited in sports by WADA. The synthesized metabolites were characterized using different advanced analytical techniques. These reference standards will be helpful to all WADA‐accredited laboratories in routine anti‐doping testing. © 2023 Society of Chemical Industry (SCI).
Collapse
Affiliation(s)
- Subarna Jyoti Kalita
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research Guwahati India
| | - Sachin Dattram Pawar
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research Guwahati India
| | - Prachi Vernekar
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research Guwahati India
| | - Mayur Arun Pawar
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research Guwahati India
| | - KS Veena
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research Guwahati India
| | - KM Abha Mishra
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research Guwahati India
| | - Kalyan Kumar Sethi
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research Guwahati India
| | - P. Radhakrishnanand
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research Guwahati India
| | - Upadhyayula Suryanarayana Murty
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research Guwahati India
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research Guwahati India
| | - Puran lal Sahu
- National Dope Testing Laboratory (NDTL) JLN Stadium Complex New Delhi India
| | - Sachin Dubey
- National Dope Testing Laboratory (NDTL) JLN Stadium Complex New Delhi India
| | - Kapendra Sahu
- National Dope Testing Laboratory (NDTL) JLN Stadium Complex New Delhi India
| | - Awanish Upadhyay
- National Dope Testing Laboratory (NDTL) JLN Stadium Complex New Delhi India
| | - Rajesh Kumar Kori
- National Dope Testing Laboratory (NDTL) JLN Stadium Complex New Delhi India
| | - Pramod Kumar
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research Guwahati India
| |
Collapse
|
6
|
Thangavelu MU, Wouters B, Kindt A, Reiss IKM, Hankemeier T. Blood microsampling technologies: Innovations and applications in 2022. ANALYTICAL SCIENCE ADVANCES 2023; 4:154-180. [PMID: 38716066 PMCID: PMC10989553 DOI: 10.1002/ansa.202300011] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/25/2023] [Accepted: 04/28/2023] [Indexed: 06/23/2024]
Abstract
With the development of highly sensitive bioanalytical techniques, the volume of samples necessary for accurate analysis has reduced. Microsampling, the process of obtaining small amounts of blood, has thus gained popularity as it offers minimal-invasiveness, reduced logistical costs and biohazard risks while simultaneously showing increased sample stability and a potential for the decentralization of the approach and at-home self-sampling. Although the benefits of microsampling have been recognised, its adoption in clinical practice has been slow. Several microsampling technologies and devices are currently available and employed in research studies for various biomedical applications. This review provides an overview of the state-of-the-art in microsampling technology with a focus on the latest developments and advancements in the field of microsampling. Research published in the year 2022, including studies (i) developing strategies for the quantitation of analytes in microsamples and (ii) bridging and comparing the interchangeability between matrices and choice of technology for a given application, is reviewed to assess the advantages, challenges and limitations of the current state of microsampling. Successful implementation of microsampling in routine clinical care requires continued efforts for standardization and harmonization. Microsampling has been shown to facilitate data-rich studies and a patient-centric approach to healthcare and is foreseen to play a central role in the future digital revolution of healthcare through continuous monitoring to improve the quality of life.
Collapse
Affiliation(s)
| | - Bert Wouters
- Metabolomics and Analytics CentreLeiden UniversityLeidenThe Netherlands
| | - Alida Kindt
- Metabolomics and Analytics CentreLeiden UniversityLeidenThe Netherlands
| | - Irwin K. M. Reiss
- Department of Neonatal and Pediatric Intensive CareDivision of NeonatologyErasmus MCRotterdamThe Netherlands
| | - Thomas Hankemeier
- Metabolomics and Analytics CentreLeiden UniversityLeidenThe Netherlands
| |
Collapse
|
7
|
Boutin M, Lavoie P, Beaudon M, Kabala Ntumba G, Bichet DG, Maranda B, Auray-Blais C. Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots. Int J Mol Sci 2023; 24:ijms24043223. [PMID: 36834643 PMCID: PMC9966246 DOI: 10.3390/ijms24043223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 01/19/2023] [Accepted: 01/26/2023] [Indexed: 02/10/2023] Open
Abstract
Fabry disease (FD) is an X-linked lysosomal storage disorder where impaired α-galactosidase A enzyme activity leads to the intracellular accumulation of undegraded glycosphingolipids, including globotriaosylsphingosine (lyso-Gb3) and related analogues. Lyso-Gb3 and related analogues are useful biomarkers for screening and should be routinely monitored for longitudinal patient evaluation. In recent years, a growing interest has emerged in the analysis of FD biomarkers in dried blood spots (DBSs), considering the several advantages compared to venipuncture as a technique for collecting whole-blood specimens. The focus of this study was to devise and validate a UHPLC-MS/MS method for the analysis of lyso-Gb3 and related analogues in DBSs to facilitate sample collection and shipment to reference laboratories. The assay was devised in conventional DBS collection cards and in Capitainer®B blood collection devices using both capillary and venous blood specimens from 12 healthy controls and 20 patients affected with FD. The measured biomarker concentrations were similar in capillary and venous blood specimens. The hematocrit (Hct) did not affect the correlation between plasma and DBS measurements in our cohort (Hct range: 34.3-52.2%). This UHPLC-MS/MS method using DBS would facilitate high-risk screening and the follow-up and monitoring of patients affected with FD.
Collapse
Affiliation(s)
- Michel Boutin
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche–CIUSSS de l’Estrie-CHUS, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
| | - Pamela Lavoie
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche–CIUSSS de l’Estrie-CHUS, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
| | - Margot Beaudon
- Institut de Pharmacologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
| | - Georges Kabala Ntumba
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche–CIUSSS de l’Estrie-CHUS, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
| | - Daniel G. Bichet
- Research Center, Hôpital du Sacré-Coeur de Montreal, University of Montreal and Nephrology Service, Montreal, QC H4J 1C5, Canada
| | - Bruno Maranda
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche–CIUSSS de l’Estrie-CHUS, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
| | - Christiane Auray-Blais
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche–CIUSSS de l’Estrie-CHUS, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
- Correspondence:
| |
Collapse
|
8
|
Joubert A, Joubert A, van der Merwe M, Norman J, Castel S, Denti P, Sliwa K, Maartens G, Sinxadi P, Wiesner L. Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay. J Mass Spectrom Adv Clin Lab 2022; 27:7-17. [PMID: 36568714 PMCID: PMC9772843 DOI: 10.1016/j.jmsacl.2022.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 12/08/2022] [Accepted: 12/08/2022] [Indexed: 12/14/2022] Open
Abstract
Introduction Adherence to medication is an important determinant of outcomes in chronic diseases like heart failure. Drug assays provide objective adherence biomarkers. Dried blood spots (DBS) are appealing samples for drug assays due to less demanding transportation and storage requirements. Objectives To analytically validate a LC-MS/MS method for the simultaneous quantification of carvedilol, enalaprilat, and perindoprilat in DBS and evaluate the feasibility of using the method as an adherence determining assay. To validate the assay further clinically by establishing correlation and agreement between plasma and DBS samples from a pharmacokinetic pilot study. Methods The method was validated over a concentration range of 1.00-200 ng/mL according to FDA guidelines. Adherence tracking ability of the assay was evaluated using a pharmacokinetic pilot study. Correlation and agreement were evaluated through Deming regression and Bland-Altman analysis, respectively. Results Accuracy, precision, selectivity, and sensitivity were proven with complete and reproducible extraction recovery at all concentrations tested. Stability of the analytes in the matrix and throughout sample processing was proven. The full range of concentrations of the pharmacokinetic pilot study could be quantified for enalaprilat, but not for carvedilol and perindoprilat. The difference between the observed and calculated plasma concentrations was less than 20 % of their mean for >67 % of samples for all analytes. Conclusions The assay is suitable as a screening tool for carvedilol and perindoprilat, while suitable as an adherence determining assay for enalaprilat. Equivalence between observed and predicted plasma concentrations proves DBS and plasma concentrations can be used interchangeably.
Collapse
Key Words
- ACE-I, Angiotensin-converting enzyme inhibitors
- ALQ, Above the Limit of Quantitation
- Adherence
- BD, Bidaily
- BMI, Body mass index
- CHF, Chronic Heart Failure
- CID, Collision-induced dissociation
- CV, Co-efficient of variation
- Carvedilol
- DBS, Dried Blood Spots
- Dried blood spots
- EMA, European Medicines Agency
- ESI, Electrospray ionization
- Enalaprilat
- HF, Heart Failure
- ISTD, Internal standard
- ITP, Initial testing procedure
- LC-MS/MS
- LC-MS/MS, Liquid Chromatography with tandem mass spectrometry
- LLOQ, lower limit of quantitation
- LOD, Limit of detection
- MRM, Multiple reaction monitoring
- NYHA FC, New York Heart Association Functional Classification
- OD, Once Daily
- Perindoprilat
- QC DIL, Quality control dilution
- QC LLOQ, Quality control lowest level of quantification
- QC, Quality Control
- QCH, Quality control high
- QCL, Quality control low
- QCM, Quality control medium
- S/N, signal-to-noise ratio
- SOP, Standard operating procedure
- ULOQ, upper limit of quantification
- VAMS, volumetric absorptive micro sampling
Collapse
Affiliation(s)
- Andre Joubert
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Anton Joubert
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Marthinus van der Merwe
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Jennifer Norman
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Sandra Castel
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Paolo Denti
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Karen Sliwa
- Cape Heart Institute, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa,Division of Cardiology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - Gary Maartens
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Phumla Sinxadi
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
| | - Lubbe Wiesner
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa,Corresponding author.
| |
Collapse
|